Bacterial antibiotic resistance is rapidly growing globally and poses a severe health threat as the number of multidrug resistant (MDR) and extensively drug-resistant (XDR) bacteria increases. The observed resistance is partially due to natural evolution and to a large extent is attributed to antibiotic misuse and overuse. As the rate of antibiotic resistance increases, it is crucial to develop new drugs to address the emergence of MDR and XDR pathogens. A variety of strategies are employed to address issues pertaining to bacterial antibiotic resistance and these strategies include: (1) the anti-virulence approach, which ultimately targets virulence factors instead of killing the bacterium, (2) employing antimicrobial peptides that target key proteins for bacterial survival and, (3) phage therapy, which uses bacteriophages to treat infectious diseases. In this review, we take a renewed look at a group of ESKAPE pathogens which are known to cause nosocomial infections and are able to escape the bactericidal actions of antibiotics by reducing the efficacy of several known antibiotics. We discuss previously observed escape mechanisms and new possible therapeutic measures to combat these pathogens and further suggest caseinolytic proteins (Clp) as possible therapeutic targets to combat ESKAPE pathogens. These proteins have displayed unmatched significance in bacterial growth, viability and virulence upon chronic infection and under stressful conditions. Furthermore, several studies have showed promising results with targeting Clp proteins in bacterial species, such as Mycobacterium tuberculosis, Staphylococcus aureus and Bacillus subtilis.
Caseinolytic proteins (Clp), which are present in both prokaryotes and eukaryotes, play a major role in cell protein quality control and survival of bacteria in harsh environmental conditions. Recently, a member of this protein family, ClpK was identified in a pathogenic strain of Klebsiella pneumoniae which was responsible for nosocomial infections. ClpK is linked to the thermal stress survival of this pathogen. The genome wide analysis of Clp proteins in Klebsiella spp. indicates that ClpK is present in only 34% of the investigated strains. This suggests that the uptake of the clpk gene is selective and may only be taken up by a pathogen that needs to survive harsh environmental conditions. In silico analyses and molecular dynamic simulations show that ClpK is mainly α-helical and is highly dynamic. ClpK was successfully expressed and purified to homogeneity using affinity and anion exchange chromatography. Biophysical characterization of ClpK showed that it is predominantly alpha-helical, and this is in agreement with in silico analysis of the protein structure. Furthermore, the purified protein is biologically active and hydrolyses ATP in a concentration- dependent manner.
Over the years, the increase in antibiotic resistant Klebsiella pneumoniae has highlighted the urgent need for the identification of novel therapeutic compounds and targets. ClpK is a caseinolytic ATPase that plays an important role in protein quality control and thermotolerance, making it a promising drug target. This study used in silico methods including ADMET screening, molecular docking and molecular dynamics simulations to evaluate binding efficiency and dynamic stability of selected natural and synthetic compounds with ClpK under varying ionic conditions. ADMET screening of synthetic and natural compounds excluded compounds violating Lipinski’s rule of 5 or showing predicted toxicity. Sclerotiamide P was identified as the top binder (-10.9 kcal/mol), while compound D3 had the weakest binding (-4.5 kcal/mol). The top ten compounds with the most favourable binding scores were then further investigated using molecular dynamics simulations in the presence of NaCl and MgCl 2 . Trajectory and MM-GBSA binding analyses confirmed that ClpK-ligand complexes remained stable in both ionic environments, with negative binding free energy values indicative of favourable interactions. Overall, the study highlighted ADEP3 and sclerotiamide derivatives as promising ClpK inhibitors and provides a foundation for further experimental validation.
Protein-protein interaction networks provide a foundation for understanding the molecular mechanisms within cells and are increasingly recognized as promising targets for therapeutic intervention. However, the experimental elucidation of these interactions is complicated by the complexity and dynamic nature of protein interaction networks. In silico methods have become invaluable allowing researchers to identify potential interactions and focus on those that may be biologically significant to guide experimental validation and drug discovery. This study employed computational modelling, visualization, and network analysis to investigate the interactions of ClpK, a Clp ATPase integral to protein homeostasis and thermotolerance of Klebsiella pneumoniae . Potential interacting partners of ClpK were predicted using the STRING database with ClpB used as a structural proxy for ClpK. The proteins with edge confidence scores greater than 0.8 were selected for molecular docking and molecular dynamics simulations to assess interaction stability and binding affinities. Molecular docking using the ClusPro server confirmed stable interactions between ClpK and its predicted partners, which were further characterised using PDBsum and Hawkdock to visualise binding interfaces and estimate binding free energies MM-GBSA calculation. Among the predicted complexes, KPN_01323 had the highest interaction score, highlighting it as the most promising candidate for further investigation. Molecular dynamics simulations further confirmed the stabilisation of putative partners upon interaction with ClpK supporting the robustness of this interaction. Collectively, these findings provide insight into the ClpK interaction network and establish a framework for future in vitro and in vivo studies contributing to elucidate the biological role and therapeutic potential of ClpK.